Evidence map›Paper›PMID 30647111›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.

Allison Gartung, Jun Yang, Vikas P Sukhatme, Diane R Bielenberg, Djanira Fernandes, Jaimie Chang, Birgitta A Schmidt, Sung Hee Hwang, David Zurakowski, Sui Huang and 3 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07607548 (A 8-week, Randomized, Double-blind, and Placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on Proinflammatory Mechanisms Induced by Systemic Treatment in Women With Breast Cancer), which is not on this map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07607548 nacompletednot on this mapstarted 2022, after this paper: background citation

A 8-week, Randomized, Double-blind, and Placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on Proinflammatory Mechanisms Induced by Systemic Treatment in Women With Breast Cancer

TypeinterventionalSponsorPoznan University of Medical SciencesRan2022 to 2024Enrolled60ConditionsBreast Cancer, Probiotic TherapyArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Allison GartungCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; agartung@bidmc.harvard.edu bdhammock@ucdavis.edu dpanigra@bidmc.harvard.edu.
Jun YangDepartment of Entomology and Nematology, University of California, Davis, CA 95616.
Vikas P SukhatmeCancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Diane R BielenbergVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
Djanira FernandesCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Jaimie ChangCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Birgitta A SchmidtDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
Sung Hee HwangDepartment of Entomology and Nematology, University of California, Davis, CA 95616.
David ZurakowskiDepartment of Anesthesia, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
Sui HuangInstitute for Systems Biology, Seattle, WA 98109.ORCID 0000-0002-3545-4665
Mark W KieranDivision of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Bruce D HammockDepartment of Entomology and Nematology, University of California, Davis, CA 95616; agartung@bidmc.harvard.edu bdhammock@ucdavis.edu dpanigra@bidmc.harvard.edu.ORCID 0000-0003-1408-8317
Dipak PanigrahyCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; agartung@bidmc.harvard.edu bdhammock@ucdavis.edu dpanigra@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USBoston Children's Hospital · USUC Davis Comprehensive Cancer CenterInstitute for Systems Biology · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
Training and Education CoreU54NS079202 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEIN, PAMELA J · 2012 to 2021
$35.7M
HYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0M
Controlling cancer with aspirin-triggered stimulation of resolutionR01CA170549 · NCI · BOSTON CHILDREN'S HOSPITAL · PI PANIGRAHY, DIPAK, SERHAN, CHARLES NICHOLAS · 2012 to 2015
$1.9M
NCI NIH HHS R01 CA170549NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R01 ES002710NINDS NIH HHS U54 NS079202
6 · The paper itself

Abstract

Although chemotherapy is a conventional cancer treatment, it may induce a protumorigenic microenvironment by triggering the release of proinflammatory mediators. In this study, we demonstrate that ovarian tumor cell debris generated by first-line platinum- and taxane-based chemotherapy accelerates tumor progression by stimulating a macrophage-derived "surge" of proinflammatory cytokines and bioactive lipids. Thus, targeting a single inflammatory mediator or pathway is unlikely to prevent therapy-induced tumor progression. Here, we show that combined pharmacological abrogation of the cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) pathways prevented the debris-induced surge of both cytokines and lipid mediators by macrophages. In animal models, the dual COX-2/sEH inhibitor PTUPB delayed the onset of debris-stimulated ovarian tumor growth and ascites leading to sustained survival over 120 days postinjection. Therefore, dual inhibition of COX-2/sEH may be an approach to suppress debris-stimulated ovarian tumor growth by preventing the therapy-induced surge of cytokines and lipid mediators.

Indexed as

AnimalsAntineoplastic AgentsBridged-Ring CompoundsCarcinoma, Ovarian EpithelialCell ProliferationCyclooxygenase 2Cyclooxygenase 2 InhibitorsCytokinesDisease Models, AnimalDisease ProgressionEpoxide HydrolasesFemaleInflammationLipidsMacrophagesMiceAntineoplastic AgentsBridged-Ring CompoundsCyclooxygenase 2Cyclooxygenase 2 InhibitorsCytokinesEpoxide HydrolasesLipidsPlatinumtaxaneTaxoidscyclooxygenasedebrisinflammationoxylipinssoluble epoxide hydrolase

Identifiers

PMID30647111
PMCPMC6358686
OpenAlexW2910435913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.